Close Menu

NEW YORK – Roche said Thursday that its diagnostics division revenues grew 2 percent  percent year over year, or 9 percent on a constant exchange rate, in the first nine months of 2020, driven mainly by COVID-19 testing.

For the nine months of 2020, the Basel, Switzerland-based company's total revenues declined 5 percent to CHF 43.98 billion ($48.12 billion) from CHF 46.07 billion during the same period in 2019. At CER, total revenues for the period rose 1 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.